Reduction of glucose metabolism in olfactory bulb is an earlier Alzheimer’s disease-related biomarker in 5XFAD mice

Chinese Medical Journal

Volumn 128, Issue 16, 2015, Pages 2220-2227

  Xiao, Nai An ^a   Zhang, Jing ^a   Zhou, Meng ^a   Wei, Zhen ^a   Wu, Xi Lin ^a   Dai, Xiao Man ^a   Zhu, Yuan Gui ^a   Chen, Xiao Chun ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

2 deoxy 2 (18F) fluoro D glucose; Alzheimer s disease; Biomarker; Olfactory bulb; Positron emission tomography computed tomography

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CASE CONTROL STUDY; COGNITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HIPPOCAMPUS; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; OLFACTORY BULB; POLYMERASE CHAIN REACTION; ANIMAL; METABOLISM; POSITRON EMISSION TOMOGRAPHY; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOMARKERS; FLUORODEOXYGLUCOSE F18; GLUCOSE; MICE; OLFACTORY BULB; POSITRON-EMISSION TOMOGRAPHY;

EID: 84939174104     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.162507     Document Type: Article

References (37)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005;366:2112-7.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 2011;377:1019-31.
3. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2006;32:158-63.
4. Richarz U, Gaudig M, Rettig K, Schauble B. Galantamine treatment in outpatients with mild Alzheimer’s disease. Acta Neurol Scand 2014;129:382-92.
5. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, et al. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A 2009;106:4501-6.
6. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009;302:2557-64.
7. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, et al. Alzhemed: A potential treatment for Alzheimer’s disease. Curr Alzheimer Res 2007;4:473-8.
8. Leroy K, Ando K, Héraud C, Yilmaz Z, Authelet M, Boeynaems JM, et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010;19:705-19.
9. Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of neurodegenerative disease. Curr Neurol Neurosci Rep 2006;6:379-86.
10. Murphy C. Loss of olfactory function in dementing disease. Physiol Behav 1999;66:177-82.
11. Hori Y, Matsuda O, Ichikawa S. Olfactory function in elderly people and patients with Alzheimer’s disease. Psychogeriatrics 2014;21:132-8.
12. Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Doty RL, et al. Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology 2015;84:182-9.
13. Marine N, Boriana A. Olfactory markers of depression and Alzheimer’s disease. Neurosci Biobehav Rev 2014;45:262-70.
14. Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, et al. Longitudinal assessment of cerebral ß-amyloid deposition in mice overexpressing Swedish mutant ß-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med 2013;54:1127-34.
15. Rojas S, Herance JR, Gispert JD, Abad S, Torrent E, Jiménez X, et al. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging 2013;34:1790-8.
16. Reiman EM, Uecker A, Gonzalez-Lima F, Minear D, Chen K, Callaway NL, et al. Tracking Alzheimer’s disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 2000;11:987-91.
17. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2008;35:2169-81.
18. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
19. Macdonald IR, DeBay DR, Reid GA, O’Leary TP, Jollymore CT, Mawko G, et al. Early detection of cerebral glucose uptake changes in the 5XFAD mouse. Curr Alzheimer Res 2014;11:450-60.
20. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci 2006;26:10129-40.
21. Nathan BP, Yost J, Litherland MT, Struble RG, Switzer PV. Olfactory function in apoE knockout mice. Behav Brain Res 2004;150:1-7.
22. Zhang J, Yang L, Lin N, Pan X, Zhu Y, Chen X. Aging-related changes in RP3V kisspeptin neurons predate the reduced activation of GnRH neurons during the early reproductive decline in female mice. Neurobiol Aging 2014;35:655-68.
23. Ma Y, Smith D, Hof PR, Foerster B, Hamilton S, Blackband SJ, et al. In Vivo 3D digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Front Neuroanat 2008;2:1.
24. Wachowiak M, Shipley MT. Coding and synaptic processing of sensory information in the glomerular layer of the olfactory bulb. Semin Cell Dev Biol 2006;17:411-23.
25. Young JW, Sharkey J, Finlayson K. Progressive impairment in olfactory working memory in a mouse model of mild cognitive impairment. Neurobiol Aging 2009;30:1430-43.
26. Van Dijck A, Vloeberghs E, Van Dam D, Staufenbiel M, De Deyn PP. Evaluation of the APP23-model for Alzheimer’s disease in the odour paired-associate test for hippocampus-dependent memory. Behav Brain Res 2008;190:147-51.
27. Edwards DA, Thompson ML, Burge KG. Olfactory bulb removal vs peripherally induced anosmia: Differential effects on the aggressive behavior of male mice. Behav Biol 1972;7:823-8.
28. Enwere E, Shingo T, Gregg C, Fujikawa H, Ohta S, Weiss S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. J Neurosci 2004;24:8354-65.
29. Gheusi G, Cremer H, McLean H, Chazal G, Vincent JD, Lledo PM. Importance of newly generated neurons in the adult olfactory bulb for odor discrimination. Proc Natl Acad Sci U S A 2000;97:1823-8.
30. Lien CW, Hisatsune T, Kaminogawa S. Role of olfaction in food preference as evaluated in an animal model. Biosci Biotechnol Biochem 1999;63:1553-6.
31. Herholz K. PET studies in dementia. Ann Nucl Med 2003;17:79-89.
32. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80:S160-7.
33. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet 2004;13:1225-40.
34. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006;15:1437-49.
35. Attems J, Walker L, Jellinger KA. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol 2014;127:459-75.
36. Wesson DW, Levy E, Nixon RA, Wilson DA. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer’s disease mouse model. J Neurosci 2010;30:505-14.
37. Díaz-Guerra E, Pignatelli J, Nieto-Estévez V, Vicario-Abejón C. Transcriptional regulation of olfactory bulb neurogenesis. Anat Rec (Hoboken) 2013;296:1364-82.